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Many proteolytic enzymes of parasitic nematodes have been identiﬁed as possible targets of control. Testing these as vaccine or drug
targets is often diﬃcult due to the problems of expressing proteases in a correctly folded, active form in standard expression systems. In
an eﬀort to overcome these diﬃculties we have tested Caenorhabditis elegans as an expression system for a Haemonchus contortus cathep-
sin L cysteine protease, Hc-CPL-1. Recombinant Hc-CPL-1 with a polyhistidine tag added to the C-terminal was expressed in an active
and glycosylated form in C. elegans. Optimal expression was obtained expressing Hc-cpl-1 under control of the promoter of the homol-
ogous C. elegans cpl-1 gene. The recombinant protein was puriﬁed from liquid cultures by nickel chelation chromatography in suﬃcient
amounts for vaccination studies to be carried out. This study provides proof of principle that active, post-translationally modiﬁed par-
asitic nematode proteases can be expressed in C. elegans and this approach can be extended for expression of known protective antigens.
 2007 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.
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The increasing problem of resistance to all classes of
anthelmintics currently available highlights the need for
novel control methods for parasitic nematodes of veteri-
nary importance (Kaplan, 2004; Sargison et al., 2005).
The absence of any new drugs nearing commercial develop-
ment has led to greater interest in vaccine development, as
well as alternative strategies including pasture manage-
ment, nutrition and selective host breeding (Stear et al.,
2007). A signiﬁcant amount of research has been carried
out on identiﬁcation and testing of potential control
targets, but translation of this to recombinant vaccine0020-7519/$30.00  2007 Australian Society for Parasitology Inc. Published b
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133, B-9820 Merelbeke, Belgium.production remains a major hurdle. A number of highly
eﬀective antigens have been identiﬁed in protection trials
against the major abomasal pathogens Haemonchus contor-
tus and Teladorsagia circumcincta in sheep (Knox et al.,
2003) and Ostertagia ostertagi in cattle (Claerebout et al.,
2003; Vercauteren et al., 2004). However, despite the suc-
cess of native proteins in inducing protective immunity,
recombinant forms expressed in bacteria, yeast or insect
cell expression systems are far less eﬀective (Newton and
Meeusen, 2003; Vercauteren et al., 2004). A few successes
have been reported, such as the ability of a Pichia pasto-
ris-expressed aspartyl protease of the dog hookworm Ancy-
lostoma caninum (Ac-APR-1) (Loukas et al., 2005) and
bacterially expressed H. contortus cysteine proteases (Red-
mond and Knox, 2006) to induce protection, although the
latter were not as eﬀective as the native proteins. The iden-
tiﬁed protective H. contortus gut antigens all have protease
activity and are all glycosylated (Knox et al., 2003).
Enzyme activity, indicative of appropriate folding, mayy Elsevier Ltd. All rights reserved.
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responses, a suggestion supported by vaccine trials with
dissociated or denatured antigen preparations, treatments
which dramatically reduce the protection observed (Munn
et al., 1997). In addition, a considerable proportion (>60%)
of the antibody generated by vaccination with gut antigens
of Haemonchus is to glycan moities (Geldhof et al., 2005;
Knox, unpublished data). It is speculated that the limited
success to date with recombinant forms, particularly of
the H11 protective gut antigen, may be due to incorrect
conformation and/or glycosylation diﬀerences between
native and standard recombinant proteins (Newton and
Meeusen, 2003).
A system which expresses parasitic nematode proteins in
a form resembling the native protein, including correct fold-
ing and appropriate post-translational modiﬁcations,
would, therefore, be advantageous to vaccine development.
The similarities in basic biology and genome sequence
between the free-living nematode Caenorhabditis elegans
and parasitic nematodes, particularly other Clade V nema-
todes such asH. contortus, suggest C. elegansmay be a suit-
able alternative expression system. Several studies have
previously demonstrated expression of parasitic nematode
genes in C. elegans.Kwa et al. (1995) showed that a b-tubu-
lin gene, tub-1, from H. contortus could confer thiabenda-
zole (TBZ) sensitivity when expressed in a C. elegans
TBZ-resistant mutant. More recently, Pillai et al. (2005)
reported expression in C. elegans of a cystatin gene from
the ﬁlarial parasite Acanthocheilonema viteae. Although
his-tagged A. vitea recombinant cystatin could be detected
in transgenic C. elegans extracts by Western blot, the
protein could not be puriﬁed by nickel chromatography,
perhaps due to inaccessibility of the tag (Pillai et al., 2005).
In a previous study, we demonstrated rescue of a C. ele-
gans cathepsin L protease mutant with the orthologous
cathepsin L gene (Hc-cpl-1) from H. contortus (Britton
and Murray, 2002). This demonstrated, ﬁrstly, correct fold-
ing and activation of the enzyme in the free-living nema-
tode and, second, functional conservation of the parasite
and C. elegans CPL-1 (Ce-CPL-1) proteases. In C. elegans,
CPL-1 is required for correct processing of yolk proteins
within developing embryos and loss of Ce-CPL-1 activity
leads to embryonic lethality (Hashmi et al., 2002; Britton
and Murray, 2004). Ce-cpl-1 is expressed in the gut and
the protein transported to the gonad via the pseudocoelo-
mic ﬂuid (Britton and Murray, 2004). Cathepsin L activity
has also been implicated in egg development in the liver
ﬂuke Fasciola hepatica, in addition to its role in feeding.
Vaccination of sheep and cattle with native F. hepatica
cathepsin L protease reduced worm burden, egg output
and egg hatching (Dalton et al., 2003). In this study, we
examine whether C. elegans is a suitable system for bulk
expression of Hc-CPL-1 and examine enzymatic activity
and post-translational modiﬁcation of the expressed prote-
ase. We also test the recombinant protein in protection
studies in sheep to determine any eﬀect on embryonic
development.2. Materials and methods
2.1. Generation of histidine tagged protein expression
constructs
2.1.1. Ce-cpl-1 promoter construct
An Hc-cpl-1 construct was previously generated in the
pGEM-T vector (Promega) containing 1.76 kb of Ce-cpl-1
upstream sequence, 512 bp of Ce-cpl-1 3 0 untranslated
region (UTR) and Hc-cpl-1 coding sequence (Britton and
Murray, 2002). To generate a polyhistidine tagged Hc-
CPL-1 expression construct (Hc-cpl-1-His), the Hc-cpl-1
coding sequence was excised from the above construct with
XbaI and SalI and a new Hc-cpl-1 insert, encoding a 10·
histidine tag at the C-terminal, was ligated into the XbaI/
SalI digested vector. The new insert was generated by
PCR ampliﬁcation of a previously isolated Hc-cpl-1 cDNA
clone using primers Hc-cpl-1-hF1 (5 0CAAACT
AGTATGCTACGTCTGTTGTCGTTGGCGC3 0; under-
line indicates start codon; italics indicate SpeI restriction
site to ligate into the XbaI restriction site of the vector)
and Hc-cpl-1-hR1 (5 0AGCGTCGACCCTAGTGGTGGT
GGTGGTGGTGGTGGTGGTGGTGAACGAGCGGG
TAGCTGGCC3 0; underline indicates complement of the
stop codon; italics indicate SalI restriction site).
2.1.2. GATA-Ce-cpl-1 promoter construct
A GATA enhancer-construct was generated containing
six copies of a GATA enhancer element from the C. elegans
cathepsin B protease cpr-1. The GATA concatamer was
excised from clone pC1562 (Britton et al., 1998) by diges-
tion with SphI and cloned into the SphI site present at
the 5 0 end of the Ce-cpl-1 promoter in the rescue construct
described above.
2.1.3. let-858 promoter construct
For cloning into C. elegans let-858 promoter vector
pPD118.25 (kindly provided by Andy Fire), His-tagged
Hc-cpl-1 was PCR ampliﬁed using primers Hc-cpl-1-LF1
(50CAAGCTAGCATGCTACGTCTGTTGTCGTTGGCG
C3 0; underline indicates start codon; italics indicate NheI
restriction site) andHc-cpl-1-LR1 (5 0AGCGCTAGCCCTA
GTGGTGGTGGTGGTGGTGGTGGTGGTGGTGAAC
GAGCGGGTAGCTGGCC3 0; underline indicates comple-
ment of stop codon; italics indicate NheI restriction site).
The PCR product was cloned initially into TOPO vector
pCR2.1 (Invitrogen), excised from pCR2.1 with NheI and
cloned into NheI digested, CIP (calf intestinal phosphatase)
treated pPD118.25 vector. Automated DNA sequencing
was carried out to conﬁrm the identity of all cloned frag-
ments (MWG Biotech).
2.2. Testing rescue activity of C. elegans-expressed
Hc-CPL-1 his-tagged protein
Plasmid DNA for each of the Hc-cpl-1-His constructs
was prepared using the Qiagen protocol and injected (ﬁnal
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(ﬁnal concentration 100 lg/ml; Kramer et al., 1990), into
the gonad of C. elegans adult hermaphrodites. Transforma-
tion was carried out in Ce-cpl-1 deletion strain VC322
(allele ok360) previously rescued with the Ce-cpl-1 wild-
type gene together with dpy-7:green ﬂuorescent protein
(GFP) as a marker gene (Britton and Murray, 2002).
The rescued strain was used as Ce-cpl-1 (ok360) homozy-
gous mutants produce 95–100% dead embryos and cannot,
therefore, be maintained. Progeny of the injected worms
which showed a roller phenotype and loss of dpy-7:GFP
were maintained and their progeny scored for embryonic
survival. Whole worm PCR using gene-speciﬁc primers
was carried out to conﬁrm that roller progeny contained
the Hc-cpl-1-His construct in a Ce-cpl-1 (ok360) homozy-
gous mutant background (Britton and Murray, 2002).
2.3. Caenorhabditis elegans culture and protein puriﬁcation
Caenorhabditis elegans worms transformed with the
Hc-cpl-1-His and rol-6 constructs were grown on 30 9-cm
normal growth medium (NGM) agar plates seeded with
Eschericia coli OP50 (Sulston and Hodgkin, 1988) at
20 C for 4 days, at which time the worms were adult stage.
To prevent starvation, worms were fed with additional
OP50 bacteria 24 h before washing oﬀ. Worms were
washed from the plates using M9 buﬀer (Sulston and
Hodgkin, 1988), left to settle on ice for 10 min and washed
a further three times to remove OP50 bacteria. For liquid
culture, Hc-cpl-1-His-transformed worms were grown ini-
tially on ﬁve 9-cm NGM agar plates for 5 days, at which
time the OP50 bacteria had cleared from the plates. Worms
were washed from the plates in M9 buﬀer and added to a
3 l ﬂask containing 500 ml S medium (Sulston and Hodg-
kin, 1988) supplemented with 28 ml of packed OP50 cul-
ture. Worms were grown at 20 C, 200 rpm for 5 days,
with 56 ml OP50 added on day 2 to prevent starvation.
Worms were separated from OP50 bacteria and worm deb-
ris by centrifugation at 1730g on a 60% (w/v) sucrose gra-
dient. Worms were collected from the upper layer, washed
three times in 0.1 M NaCl and once in M9 buﬀer, by allow-
ing them to settle on ice. Worms from the agar plates or
liquid culture were homogenised in M9 on ice using a stan-
dard glass homogeniser. The worm extract was centrifuged
at 16,060g for 15 min and the supernatant collected. This
was applied to a 2 ml column packed with ProBond Nickel
Chelating Resin (Invitrogen) previously charged with Ni2+
ions, according to the manufacturer’s instructions. The
worm supernatant was left to bind to the column using
gentle agitation for 1 h at room temperature. The column
was then left to settle under gravity and the unbound
supernatant collected. The column was washed four times
in native wash buﬀer according to the manufacturer’s
instructions and the bound material eluted with 8 ml native
elution buﬀer containing 400 mM imidazole. Initial Wes-
tern blot studies indicated eﬃcient binding and elution of
the Hc-CPL-1-His protein from the column. The elutedsample was concentrated using Centricon 10 devices
according the manufacturer’s instructions (Amicon) and
dialysed against PBS. Protein concentration of the concen-
trated sample was estimated using the Coomassie Protein
Assay Reagent (Pierce).
2.4. SDS–PAGE and Western blotting
Adult total worm extracts were prepared by washing
hermaphrodites in M9 buﬀer and heating to 100 C for
15 min in lysis buﬀer (50 mM Tris pH 7.5, 2 mM phenyl-
methylsulfonyl ﬂuoride (PMSF, Sigma), 1 mM EDTA,
10 lM L-trans-epoxysuccinyl-leucylamido-(4-guanidino)-
butane (E64, Sigma)) containing 5% SDS and 5%
b-mercaptoethanol. For comparison of protein expres-
sion levels equal numbers of age-matched worms were
picked into M9 buﬀer and lysed as above. Before loading
onto gels, samples were boiled for 10 min in an equal
volume of loading buﬀer (lysis buﬀer containing 10%
glycerol and 0.1% Bromophenol blue). Proteins were sep-
arated on 10% SDS–polyacrylamide gels using the Bio-
Rad mini-system and blotted into polyvinylidene ﬂuoride
(PVDF) membrane. Western blotting was carried out by
standard procedure using an antibody to the mature
region of Ce-CPL-1 (Britton and Murray, 2004; 1:200
dilution) and an anti-His tag antibody (Invitrogen;
1:500 dilution). Alkaline phosphatase conjugated second-
ary antibodies (Molecular Probes) were used routinely at
1:3000 dilution. Substrate gel analysis was carried out
essentially as described by Geldhof et al. (2000), using
0.1% ﬁnal concentration of gelatin (Heussen and
Dowdle, 1980).
2.5. Enzyme activity assays
The synthetic substrates carbobenzoxy-arginyl-arginyl
7-amino-4-methyl coumarin (Z-Arg-Arg-AMC) and car-
bobenzoxy-phenylalanyl-arginyl 7-amino-4-methyl cou-
marin (Z-Phe-Arg-AMC) (Sigma) were used to measure
cathepsin L and B activities. Z-Arg-Arg-AMC is selective
for cathepsin B activity, while both cathepsin L and B
show activity with Z-Phe-Arg-AMC substrate (Hasnain
et al., 1993). Stock solutions of the substrates were pre-
pared in methanol at a concentration of 200 lM. The
assay mixture contained 10 ll of the puriﬁed recombinant
cathepsin L (approximately 5 lg protein), 5 ll 0.1 M
dithiothreitol (DTT), 5 ll AMC substrate (ﬁnal concen-
tration 9 lM) and 90 ll of buﬀer (pH 3 and 4: 0.1 M ace-
tate buﬀer, pH 5 and 6: 0.1 M phosphate buﬀer, pH 7:
0.1 M Tris buﬀer). For inhibition assays, the cysteine pro-
tease inhibitor E64 was added to the reaction mixture at
a ﬁnal concentration of 100 lM. The release of the ﬂuo-
rescent group, AMC, was monitored with a ﬂuorescent
spectrophotometer (Perkin-Elmer, UK) (excitation wave-
length: 370 nm, emission wavelength: 450 nm) during
300 s. Results were calculated as the change in ﬂuores-
cence over the 300 s period.
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Samples of approximately 1 lg of protein, eluted from
the Nickel column, were incubated at room temperature
for 1 h with various concentrations (0–500 U) of PNGase
F in digest buﬀer according to the manufacturer’s instruc-
tions (New England Biolabs). Ten microlitres of SDS–
PAGE loading buﬀer was added to the samples, which
were then boiled for 10 min and loaded onto a 10% SDS
polyacrylamide mini-gel. Western blotting was carried
out as described above.
To examine binding to Concanavalin A lectin (Con
A), 400 ll (approximately 200 lg) puriﬁed protein in run-
ning buﬀer (10 mM Tris pH 7.4, 100 mM NaCl, 1 mM
CaCl2, 0.1 mM MnCl2, 0.5% (v/v) Triton X-100) was
applied to a 1 ml column of packed Con A agarose
(Sigma) and incubated for 1 h with agitation. The col-
umn was left to settle under gravity and unbound pro-
tein collected following three washes with running
buﬀer. A bound sample was eluted with 0.1 M methylm-
annopyranoside, followed by 0.1 M HCl. The HCl eluted
fractions were collected into 2 M Tris to neutralise the
acid. All fractions were concentrated using Centricon
devices, dialysed against PBS and Western blotting car-
ried out with anti-Ce-CPL-1 antibody as described
above.
2.7. Protection trial with C. elegans-expressed Hc-CPL-1
Five-month-old worm-free Suﬀolk lambs were
allocated into groups of seven, balanced for sex and
weight. One group received three immunisations (each
70 lg C. elegans expressed cathepsin L protein) at 3
weekly intervals and were challenged with 5000 infective
L3 H. contortus 1 week after the ﬁnal immunisation. Five
milligram Quil A was used as adjuvant and the ﬁnal vol-
ume was adjusted to 2 ml with PBS. This was adminis-
tered i.m. as two 1 ml doses into each hind leg, with
control animals receiving adjuvant alone. Blood was sam-
pled at weekly intervals and faecal egg counts (FEC)
monitored three times weekly from day 16 after challenge
until necropsy at days 34–36 when worm numbers were
counted, as previously described (Smith and Smith,
1993). All procedures were carried out in accordance with
the Animal (Scientiﬁc Procedures) Act and approved by
the Moredun Ethical Committee.
2.8. ELISA
Microtitre plates were coated overnight at 4 C with
2 lg/ml C. elegans-expressed Hc-CPL-1-His protein
diluted in 50 mM bicarbonate buﬀer, pH 9.6. Total
IgG titres for individual animals were measured as
described previously (Redmond and Knox, 2004) and
values expressed as the dilution factor required to obtain
the mean of the group pre-immune serum values at a
dilution of 1:20.2.9. Immunolocalisation
Haemonchus contortus adult worms (33 days old) were
embedded in paraﬃn wax and transverse sections cut
and probed with pooled pre-immune or cathepsin L
immune sera from vaccinated animals at a 1:100 dilution
as described previously (Redmond et al., 2004). Fluores-
cein isothiocyanate (FITC)-labelled rabbit anti-sheep IgG
was used at a dilution of 1:200. Sections were viewed
under a ﬂuorescence microscope (Olympus BX50) and
images captured using a digital camera (Olympus
DP70) at 200· magniﬁcation.3. Results
3.1. Rescue of C. elegans cpl-1 mutant with his-tagged
Hc-cpl-1
We previously reported rescue of Ce-cpl-1 RNA
interference (RNAi) or genetic mutants with the homol-
ogous Hc-cpl-1 gene (Britton and Murray, 2002). In the
present study, we aimed to determine whether active
protease could be expressed in C. elegans and puriﬁed
in suﬃcient quantities for the protease to be tested in
protection studies. An Hc-cpl-1 construct encoding a
10· histidine tag at the C-terminus of the protein
(Hc-CPL-1-His) was generated and expressed in Ce-
cpl-1 genetic mutant (ok360), using the rol-6 gene as a
marker of transformation. The histidine tagged con-
struct gave 95% rescue of the Ce-cpl-1 mutant pheno-
type, identical to that observed with the non-histidine
tagged construct (Britton and Murray, 2002). Addition
of the C-terminal tag, therefore, had no eﬀect on
expression or activity of the Hc-CPL-1 protease.
As Ce-cpl-1 is required maternally for embryonic
development (Britton and Murray, 2004), it was neces-
sary to inject Ce-cpl-1 mutant adult hermaphrodites
which had previously been rescued with the Ce-cpl-1
wild-type gene, together with dpy-7:GPF as a marker
gene, to allow development of viable embryos. All three
roller lines obtained following microinjection of the Hc-
cpl-1-His construct with rol-6 as a marker gene had lost
the original Ce-cpl-1/dpy-7::GFP array and carried only
the Hc-cpl-1/rol-6 array, as conﬁrmed by PCR with spe-
cies-speciﬁc cpl-1 PCR primers. In addition to transfor-
mation of the Ce-cpl-1 mutant strain, the C. elegans
wild-type N2 Bristol strain was also transformed with
the Hc-cpl-1-His construct. Similar numbers of transfor-
mants were obtained and identical levels of protein
expression were observed, with both strains using total
worm extracts on Western blots probed anti-his tag or
anti-Ce-CPL-1 antibodies (Fig. 1A). No reactivity was
observed with extracts from non-rescued Ce-cpl-1
(ok360) homozygous mutant worms, indicating speciﬁc
recognition of the expressed H. contortus CPL-1 protease
(data not shown).
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Fig. 1. Detection of Caenorhabditis elegans-expressed Haemonchus contortus CPL-1 protease. (A) Comparison of Hc-CPL-1-His protein in total adult
worm extracts of C. elegans N2 wild-type (WT) and cpl-1 (ok360) mutant worms transformed with Hc-cpl-1-His expression construct (75 adults per lane).
The Western blot was probed with anti-His (C-terminal) antibody. (B) Coomassie staining of concentrated eluate following Nickel aﬃnity
chromatography of the soluble fraction of Hc-cpl-1 transgenic C. elegans. (C) Western blot of aﬃnity column eluate probed with antibodies to the mature
region of Ce-CPL-1 and to the histidine tag. Mr indicates molecular mass marker proteins.
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liquid cultures
Addition of the histidine tag allowed puriﬁcation of
C. elegans-expressed Hc-CPL-1 by nickel chelation chro-
matography. In initial studies, worms were cultured on
30 9-cm NGM plates and yielded approximately 200 lg
puriﬁed Hc-CPL-1 from approximately 1 ml of packed
worms. To increase the amount of puriﬁed protein
obtained, liquid cultures (500 ml) were used and yielded
approximately 2 mg puriﬁed cathepsin L protein from
around 12 ml packed worms. Solid and liquid cultures of
transgenic C. elegans were, therefore, equally eﬃcient in
producing Hc-CPL-1. The volume of liquid culture and
all subsequent cleaning, homogenisation and puriﬁcation
procedures were easily manageable.
Analysis of protein eluted from the nickel column by
SDS–PAGE and Coomassie staining showed the presence
of a major band of approximately 41 kDa with very little
contamination with other proteins (Fig. 1B). Western blot-
ting with anti-His tag and anti-Ce-CPL-1 antibodies (Brit-
ton and Murray, 2004) conﬁrmed that the major 41 kDa
protein staining with Coomasssie was Hc-CPL-1-His
(Fig. 1C).0
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Fig. 2. Enzymatic activity of Caenorhabditis elegans-expressed Hc-CPL-1-
His with Z-Phe-Arg-AMC substrate. Activity was measured at various pH
values in the presence of dithiothreitol (DTT) (A) and at pH 5 in the
presence or absence of DTT and E64 inhibitor (B). Results are shown as
the change in ﬂuorescence over a period of 300 s.3.3. Caenorhabditis elegans-expressed Hc-CPL-1-His is
enzymatically active and glycosylated
Rescue of the Ce-cpl-1 mutant phenotype with Hc-cpl-1-
His indicated that the expressed protease was active and
capable of carrying out the same enzymatic activity as
Ce-CPL-1. Presence of enzymatic activity was also
conﬁrmed by gelatin substrate SDS–PAGE of the puriﬁed
protein. A zone of activity at approximately 41 kDa
was observed which overlayed the Coomassie stained
band in Fig. 1B (not shown). To characterise the activity,
puriﬁed Hc-CPL-1-His was incubated with the standardﬂuorogenic cysteine protease substrates Z-Phe-Arg-AMC
and Z-Arg-Arg-AMC. The protein showed activity against
Z-Phe-Arg-AMC, but not with the cathepsin B substrate
Z-Arg-Arg-AMC. Optimum activity was detected at pH 5,
indicating that Hc-CPL-1-His has typical cathepsin L activ-
ity (Fig. 2A). This activity was enhanced in the presence of
the reducing agent DTT and inhibited by E64, indicating it
is a typical cysteine protease (Fig. 2B).
Ce-CPL-1 has one potential N-linked glycosylation site
which is conserved in Hc-CPL-1 and other parasitic nema-
tode CPL-1 proteases (Britton and Murray, 2002). To
examine glycosylation of Hc-CPL-1 expressed in C. ele-
gans, puriﬁed Hc-CPL-1-His was incubated with various
concentrations of PNGase F to remove N-linked glycans.
This treatment led to a reduction of 2–3 kDa in the size
of the Hc-CPL-1 protein, with no apparent intermediate
sizes, indicating the presence of an N-linked glycan
Fig. 3. PNGase F deglycosylation of Hc-CPL-1-His. Aﬃnity puriﬁed
protein was incubated with diﬀerent units (U) of PNGase F (a, 0 U; b,
0.5 U; c, 5 U; d, 50 U; e, 500 U) for 1 h and analysed by Western blotting
with anti-His antibody.
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not been carried out, this protease was identiﬁed as a minor
protein present in an H. contortus fraction eluted from a
Con A aﬃnity column (Geldhof and Knox, unpublished
data). To examine lectin binding of puriﬁed Hc-CPL-1-
His, the protein was applied to a Con A-agarose column.
Western blotting with anti-Ce-CPL-1 antibody of fractions
eluted with methylmannopyranoside and HCl demon-
strated the presence of the Hc-CPL-1 protein (not shown).
3.4. Expression of Hc-cpl-1-His under control of diﬀerent
C. elegans promoter and enhancer regions
The yield of protein from liquid cultures of transgenic
C. elegans was suﬃcient for biochemical analysis and
vaccine trials. To examine whether it was possible to
increase expression of Hc-cpl-1-His, a GATA concata-
mer was inserted upstream of the 1.76 kb Ce-cpl-1 pro-
moter region used in the original construct. The
GATA enhancer was derived from C. elegans cpr-1
cathepsin B gene promoter and was previously shown
to enhance expression of a lacZ reporter gene in gut
and hypodermal cells (Britton et al., 1998). Hc-CPL-1-
His expressed under control of the GATA enhancer-con-
taining promoter was able to eﬃciently rescue the
Ce-cpl-1 mutant phenotype and Western blot analysis
showed expression of Hc-CPL-1-His protein. However,
the protein expression level with the GATA enhancer-
construct was slightly lower than that with the Ce-cpl-
1 promoter alone (not shown).Table 1
Faecal egg counts (FEC), adult worm burden and packed cell volume (PCV)
Group Adjuvant control
Animal number Mean FEC Adult worms PCV v
A 1928 2150 28
B 2564 2600 22
C 1195 4650 30
D 1014 3050 28
E 943 4800 32
F 1271 2650 27
G 1383 1650 31
Mean 1471 3079 28
SEM 219 456 1.25
% protection n/a n/a n/a
Mean FEC represent the cumulative means for each animal from day 16 to en
actual count in a 2% sample. PCV values are haematocrit value.Expression of Hc-CPL-His under control of the C. ele-
gans let-858 promoter was also examined. Caenorhabditis
elegans let-858 is expressed in all cells throughout develop-
ment and has been used previously to direct expression of
C. elegans and non-C. elegans genes (Paschinger et al.,
2004; Pillai et al., 2005). Although we obtained C. elegans
transgenic lines carrying the Hc-cpl-1-His construct under
control of the let-858 promoter, as indicated by PCR
analysis, this construct did not rescue the Ce-cpl-1 mutant
phenotype and no protein could be detected by Western
blot analysis with anti-Ce-CPL-1 or anti-His tag
antibodies.3.5. Protection trial and antibody response to vaccination
with Hc-CPL-1-His
A protection trial was carried out with C. elegans-
expressed Hc-CPL-1 to examine any eﬀects, particularly
on egg development. The FEC, adult worm burden and
packed cell volume (PCV) at necropsy for the cathepsin
L vaccinated and adjuvant control groups are shown in
Table 1. No reduction in FEC and worm burden was
observed in the vaccinated group and no diﬀerence in
PCV values was measured. FEC from day 16 post-chal-
lenge to necropsy on day 33 showed no signiﬁcant diﬀer-
ence between the vaccinated and adjuvant control groups
(data not shown). There was also no reduction in numbers
of larvae hatching from eggs of Hc-CPL-1 vaccinated ani-
mals. Despite this lack of protection against challenge, high
titres of total IgG to Hc-CPL-1-His were measured in
ELISA in the cathepsin L vaccinated group. The antibody
response in the adjuvant control group was negligible
(Table 2).3.6. Immunolocalisation on adult H. contortus sections
Transverse sections of H. contortus adult worms were
probed with pooled pre-immune serum or pooled anti-
cathepsin L serum collected at necropsy from vaccinated
animals. Strong staining was observed around developingat necropsy
Cathepsin L vaccinated
alues Mean FEC Adult worms PCV values
1634 2750 26
1547 3550 27
1271 3350 26
1472 6150 28
1756 5950 26
1853 3750 30
2052 2600 28
1655 4014 27
98 548 0.565
12.5 30.4 3.7
d of trial. Adult worms are total worm burden at necropsy estimated from
Table 2
Anti-Hc-CPL-1 IgG antibody titres
Group Adjuvant control Cathepsin L vaccinated
Animal number Total IgG titre Total IgG titre
A 83 77 778
B 250 34 292
C 211 54 344
D 504 108 755
E 96 115 308
F 112 33 920
G 59 103 345
Mean 188 75 392
SEM 59 13 224
IgG values are expressed as the dilution factor required to obtain the mean
of the group pre-immune serum values at a 1:20 dilution.
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serum from the cathepsin L vaccinated group (Fig. 4A). No
staining was observed in any other tissues, including the
gut. Probing with pre-immune serum resulted in no
staining of any tissues (Fig. 4B).Fig. 4. Immunolocalisation of pooled antisera from the cathepsin L
vaccinated group (A) and pre-immune serum from the same group (B) on
adult Haemonchus contortus transverse sections. The uterus containing
developing eggs is indicated by an arrowhead and the microvillar surface
of the gut is indicated by an arrow. This image is typical of many sections
incubated with these antisera. The diameter of sections is approximately
300 lm.4. Discussion
The reported failure of recombinant forms of identiﬁed
protective parasite antigens to induce protective immunity
is thought to be due to inappropriate folding and/or glyco-
sylation. This led us to examine the suitability of C. elegans
as an alternative expression system, focussing on the
H. contortus cathepsin L cysteine protease Hc-CPL-1. Sev-
eral studies have previously shown that C. elegans can be
used as a surrogate system for expression and analysis of
parasitic nematode proteins (Kwa et al., 1995; Redmond
et al., 2001; Britton and Murray, 2002; Kampko¨tter et al.,
2003; Pillai et al., 2005). This study is the ﬁrst to show that
recombinant protein can be expressed and puriﬁed from
extracts of transgenic C. elegans in suﬃcient amounts for
protection studies to be carried out. Moreover, we show
that the expressed protease is enzymatically active and
glycosylated. PNGAse F digestion demonstrated the
presence of one N-linked glycan on C. elegans-expressed
Hc-CPL-1, consistent with glycosylation predicted from
sequence analysis of nematode CPL-1 proteins identiﬁed
to date (Britton and Murray, 2002) and shown experimen-
tally to be the only N-glycosylation site on Ce-CPL-1
(Fan et al., 2005). Although similarity in glycan structures
in native and C. elegans-expressed proteins will require
detailed mass spectrometric analysis, this study provides
proof of principle that biologically active and post-transla-
tionally modiﬁed parasitic nematode protein can be
expressed inC. elegans in suﬃcient amounts for biochemical
and immunisation studies.
Although this study focussed on Hc-CPL-1, it can poten-
tially be used to test expression, activity and modiﬁcation of
any parasitic nematode protein. Of particular interest will be
previously identiﬁed protective gut antigens ofH. contortus,
such as the aminopeptidase H11 and the cathepsin B
proteases, known to be glycosylated (Knox et al., 2003).Protection trials with bacterially expressed H. contortus
cathepsin B proteases resulted in moderate but signiﬁcant
decreases in worm burden and egg output (Redmond and
Knox, 2006) and it will be important to test whether this
can be enhanced with C. elegans-expressed forms. H11 is
the most eﬀective vaccine candidate identiﬁed (Smith et al.,
1993) and detailed glycan analysis ofH11 shows the presence
of an unusual, highly fucosylated structure (Haslam et al.,
1996) which may enhance immunogenicity. It is speculated
that the inability of recombinant H11 expressed in baculovi-
rus to induce protection may be due to inappropriate glyco-
sylation (Newton and Meeusen, 2003). Interestingly, initial
studies suggest that nematode fucosylated glycans may be
involved in inducing Th2 responses in mice (Tawill et al.,
2004). Analysis of the C. elegans glycome is progressing
(Haslam and Dell, 2003; Hanneman et al., 2006) together
with identiﬁcation and functional analysis of many of the
enzymes involved in glycosylation (Schachter, 2004). The
C. elegans system and the availability of glycosylation
mutants will allow more detailed examination of parasite
glycans and their possible role(s) and eﬀects on the host
immune response (Dell et al., 1999) than is possible using
standard expression systems.
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worms andCe-cpl-1mutant worms were identical indicating
that expression of both theC. elegans and parasite proteases
is not detrimental to worm development. This suggests that
availability of aC. elegans genetic mutant is not a pre-requi-
site for expression of a related parasite gene. Hc-CPL-1 was
expressed under the control of theCe-cpl-1 promoter, which
produced suﬃcient protein for analysis and immunisation
trials. Addition of GATA motifs, which previously
enhanced expression from the Ce-cpr-1 cathepsin B pro-
moter (Britton et al., 1998) or use of the ubiquitously active
Ce-let-858 promoter (http://www.wormbase.org), resulted
in reduced expression compared with the Ce-cpl-1 promoter
alone. This suggests that strong over-expression or inappro-
priate temporal and/or spatial expression may be detrimen-
tal and may lead to low level expression or silencing of
introduced transgenes. Our ﬁndings suggest that, where pos-
sible, use of the promoter region of a related C. elegans gene
is likely to lead to optimal expression levels of introduced
parasite genes. Where this is not possible, use of a tissue-spe-
ciﬁc C. elegans promoter, such as cpr-5 for gut-speciﬁc
expression (Redmond et al., 2001), may be better than ubiq-
uitous expression.
In the present study, the Hc-cpl-1 gene was maintained
in transformed C. elegans as an extrachromosomal array,
along with the rol-6 marker gene, rather than being inte-
grated into the genome. In C. elegans, extrachromosomal
arrays are lost at each generation and the Hc-cpl-1 con-
struct was maintained in around 70–80% of the population.
This did not present a problem as the expression studies
were carried out in Ce-cpl-1 (ok360) mutant strain which
produces inviable progeny and non-transformed worms
were not maintained in the population. Integration of
low-copy arrays can be readily achieved by irradiation of
transformants, by introducing DNA by biolistic bombard-
ment or by standard microinjection with transgene DNA
together with a single stranded DNA oligo (Praitis et al.,
2001; Evans, 2006). As well as obtaining 100% transfor-
mants, integration may lead to more stable expression
and reduce any silencing eﬀects of multi-copy arrays, if this
occurs.
Ce-CPL-1 is essential during embryonic development for
correct processing of yolk proteins (Britton and Murray,
2004) and rescue of the C. elegans embryonic lethal pheno-
type with Hc-cpl-1 suggested conservation of function.
Native Hc-CPL-1 has not been tested in protection trials
due to the diﬃculty of obtaining suﬃcient quantities from
parasite extracts.We examinedwhether vaccination of sheep
with C. elegans-expressed Hc-CPL-1 provided any protec-
tion against challenge infection. No eﬀects were observed
on embryonic development, egg hatching nor on adult
worms. Animals vaccinated with the recombinant protein
produced signiﬁcant antibody (IgG) titres to the recombi-
nant protease and anti-vaccine antiserum bound strongly
to developing eggs within the uterus in worm sections. How-
ever, no binding of antibody was detected in worms recov-
ered at necropsy from immunised animals. This suggeststhat Hc-CPL-1 within the gonad in intact worms is inacces-
sible to antibody, at least in suﬃcient amounts to interfere
with function. This is in contrast to gut antigens ofH. contor-
tus which, although considered hidden, are bound by circu-
lating antibodies following vaccination with native protein
(Knox et al., 2003). An alternative explanation for lack of
protection is that additional proteases may compensate for
immune-mediated inactivation of Hc-CPL-1. C. elegans
expresses at least four cathepsin L-like enzymes (F41E6.6,
R09F10.3, R07E3.1 and cpl-1; http://www.wormbase.org)
and sequences related to these can be identiﬁed inH. contor-
tus expressed sequence tag (EST) and genome sequence data
(currently estimated at 95% genome coverage; http://
www.sanger.ac.uk/Projects/H_contortus/). The lethal phe-
notype of Ce-cpl-1 mutants indicates compensation does
not occur in this nematode but we cannot rule this out for
H. contortus.
Wepreviously showed that Ce-CPL-1 is transported from
the gut to the uterus as a pro-enzyme (Britton and Murray,
2004). In the present study, the Hc-CPL-1 protease puriﬁed
from C. elegans adult worm extracts, and used in vaccina-
tion, was predominantly in the pro-form rather than the
mature enzyme. This, most likely, explains the lower amount
of activity measured with Z-Phe-Arg-AMC than may be
expected. However, the rescue studies clearly demonstrated
that the pro-enzyme was correctly folded and could be eﬃ-
ciently activated, indicating no inherent problem with the
C. elegans-expressed protease. It seems unlikely that use of
the Hc-CPL-1 pro-enzyme led to ineﬀective protection. Pre-
vious studies used the cathepsin L pro-enzyme of F. hepatica
to induce protection: the mature protease was not used due
to degradation problems (Dalton, personal communica-
tion). AlthoughHc-CPL-1 seems not to be an eﬀective target
of immune-mediated control ofH. contortus, we have estab-
lished that active, glycosylated parasite enzyme can be
expressed and puriﬁed from transgenic C. elegans in suﬃ-
cient amounts for biochemical analysis, vaccine testing or
in vitro screening of inhibitors (Choe et al., 2005). This sys-
tem can be extended to other parasite proteins and will be
particularly important for expression of complex glycan epi-
topes and examination of their inﬂuence on the immune
response to parasitic nematodes.Acknowledgements
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